SciNeuro Pharmaceuticals, a Chinese manufacturer of drugs for central nervous system (CNS) diseases, said that it has garnered $100 million in a Series A round funding jointly led by Lilly Asia Ventures (LAV) and Arch Venture Partners.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
